Like many biotech entrepreneurs in the late 1990s, Randy Scott, then at Incyte Genomics, and George Poste of SmithKline Beecham believed that sequencing the human genome held great promise for developing new medicines. But a faster route to translating genomic data into profits, they thought, would be to focus initially on finding biomarkers predictive of disease. So they founded DiaDexus in September 1997, and with $25 million in start-up funds from Incyte and SB, Scott and Poste set out to prove it.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.